News

Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products.…

Chiesi Group and Oak Hill Bio Holdings have announced the completion of patient enrollment in the Phase 2b FOOTPRINTS study evaluating OHB-607 for the prevention of bronchopulmonary dysplasia (BPD), a leading cause of chronic lung disease in premature infants for which there are currently no…

Parma, Italy – 18 May 2026 Chiesi announces that the U.S. Food and Drug Administration (FDA) has approved its single-inhaler triple therapy (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; BDP/FF/G ) for the maintenance treatment of asthma in adults. The approval was supported by two…

Parma, Italy – 18 December 2025 Chiesi announces the submission of the Carbon Minimal pressurised metered-dose inhaler (pMDI) containing beclometasone in 100 mcg and 200 mcg strengths to the UK Medicines and Healthcare products Regulatory Agency (MHRA) on 5 th December 2025. This submission is part…

Chiesi Group today announced its decision to conclude all clinical trials for the tanimilast program in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This decision follows the full analysis of the Phase 3 PILASTER Main Cohort study in COPD, which did not meet its primary and key secondary…

Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic obstructive pulmonary disease (COPD). The study did not meet its primary and secondary endpoints. There were no safety signals observed during the study. The company would like to thank the…

Chiesi, an international research-focused healthcare Group (Chiesi Group) and Inhibrx, Inc. (“Inhibrx”), a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced today they entered into an agreement granting Chiesi Group an option to…